Abstract

In order to study the changes of CD4⁺CD25⁺Foxp3⁺Treg cells and Th1Th2 cells in subcutaneous specific immunotherapy for allergic asthma, patients with allergic asthma in Yuhuangding Hospital were selected as the research subjects and either routine drug treatment or subcutaneous specific immunotherapy were given. Serum house dust mite sIgE, allergen skin prick test, pulmonary ventilation function test www.ijpsonline.com 98 Indian Journal of Pharmaceutical Sciences Special Issue 2, 2020 and bronchial provocation test were performed, respectively, so as to test the basic condition of the patients. Then changes in CD4⁺CD25⁺Foxp3⁺Treg cells and Th1Th2 cells in the control group (routine drug treatment) and specific immunotherapy group were determined by isolating and culturing the human peripheral mononuclear cells followed by flow cytometry before and after treatment. The results showed that percent of nTreg cells in CD4⁺T cells and the percentage of Th1/Th2 cells in the control group increases to some extent after treatment, but the difference was not statistically significant. After subcutaneous specific immunotherapy, the percentage of CD4⁺CD25⁺Foxp3⁺Treg cells in CD4⁺T cells and the percentage of Th1/Th2 cells in the specific immunotherapy group increased significantly. The percentage of Th1 cells in CD4⁺T cells was positively correlated with that of CD4⁺CD25⁺Foxp3⁺Treg cells in CD4⁺T cells. Therefore, subcutaneous specific immunotherapy has a significant effect on allergic asthma. Its mechanism of action appears to be through increasing the percentage of CD4⁺CD25⁺Foxp3⁺Treg cells and Th1 cells to CD4⁺T cells, thereby increasing the proportion of Th1/Th2 cells. Despite some shortcomings in this investigation, it still provided a basis and ideas for further research.